Biofilm Monitoring and Verification: What the Evidence Can and Cannot Show

Why verification is harder than it looks

Biofilm lives on surfaces; monitoring mostly samples water. Residual measurements describe the disinfectant in the water at a tap, culture describes what grew from a small volume of that water, and neither directly interrogates the pipe wall. Verification therefore rests on triangulation: operational data (residuals, temperatures, flow, turnover), microbiological data (culture, and where justified culture-independent methods), and physical evidence (inspection, coupons or sampling devices, deposits).

Each line has a blind spot. Residuals can be satisfactory at a sentinel tap while dead legs stagnate. Culture misses viable but non-culturable cells. Sequencing detects DNA from dead cells. Coupons show what grew on a coupon, not on forty-year-old iron. Good verification states which question each result answers.

What the common methods actually measure

Culture (heterotrophic plate counts, indicator organisms, Legionella and Pseudomonas culture) measures organisms that grow under the test conditions; it is the regulatory backbone and is comparable over time, but it under-reports stressed and matrix-embedded cells. ATP measurement gives a rapid total-biomass signal without identifying organisms. Flow cytometry counts cells and, with stains, distinguishes intact from damaged membranes. Quantitative PCR and 16S rRNA amplicon sequencing detect and characterise DNA; they are sensitive and reveal community composition, but DNA is not viability and sequence similarity is not species-level identification of a pathogen. Coupons and in-situ sampling devices expose a defined surface in the system so biofilm can be removed and analysed.

Inspection, whether visual, borescope or by removing fittings, remains the most direct evidence of biofilm and deposits, and should be recorded photographically.

Bulk-water testing versus pipe-surface biofilm: the 2026 Valencia study

A study published in World Journal of Microbiology and Biotechnology on 3 August 2026 (Volume 42, article 443; doi 10.1007/s11274-026-05101-x) installed in-situ biofilm sampling devices in an operational, chlorinated drinking-water distribution network in Valencia, Spain, and followed them for a year, removing biofilm every three months. Bulk water was tested by the standard methods used for compliance (faecal indicator bacteria and pathogens) together with physicochemical parameters, disinfection by-products, geosmin and metals, and both water and biofilm were characterised by 16S rRNA gene sequencing.

The headline result is the disconnect between the two matrices. No faecal indicator bacteria or pathogens were detected in any water sample across the year. Yet DNA sequencing of the biofilms, particularly those aged six and nine months, showed sequences related to potential opportunistic pathogens including Legionella spp. and Staphylococcus spp. A core community dominated by Pseudomonas spp. and Acidovorax spp. was found in both water and biofilm; the biofilm went through a clear succession with diversity peaking mid-development, and regrowth after sampling was not seasonal. Disinfection by-products rose in the warmer months when chlorine dosing was higher (above 0.5 mg/L as Cl₂ in June and September) alongside higher iron and manganese.

What the Valencia study does and does not establish

It establishes that, in a real chlorinated network meeting its water-quality standards, pipe-wall biofilm carried DNA of organisms the bulk-water compliance tests did not find, and that in-situ sampling devices are a workable way to watch biofilm develop without interrupting supply. That is a direct demonstration of the bulk-water blind spot that this guide describes.

Two qualifications are essential. First, the biofilm findings are DNA detections: 16S sequences 'related to' Legionella or Staphylococcus do not prove that viable, infectious cells of a pathogenic species were present, and the study did not attempt culture or viability testing of those organisms in the biofilm. Second, the disinfectant maintained in the distribution network was chlorine. The treatment works used chlorine dioxide for primary disinfection at the plant, but final disinfection was UV and chlorination, and the network residual discussed in the paper is free chlorine. The study therefore says nothing about chlorine dioxide's performance in distribution, and nothing about any ChloroKlean product. It was one network in one Mediterranean city over one year.

A proportionate verification framework

Define what 'under control' means for the system in advance, with the responsible person and in line with the relevant guidance (for UK building water systems, HSE's HSG274). Choose sentinel and representative points that include worst-case locations, not only convenient ones. Record residuals, temperatures and flow alongside microbiology so that a result can be explained. Use culture for compliance and trend, and add ATP, flow cytometry, qPCR or coupons where risk, history or an unexplained result justifies them, stating in the record what each method can and cannot show. Where DNA-based results are used, say explicitly that they indicate presence of genetic material, not confirmed viable infection risk, and decide beforehand what action a positive will trigger.

Finally, treat a clean set of bulk-water results after a disinfection intervention as necessary but not sufficient. Surface evidence, trend over subsequent months and the absence of recurrence are what verify control.

Evidence and uncertainty

Published biofilm studies are valuable for understanding mechanisms, but their conditions may not match a particular installation. Species, surfaces, deposits and operating conditions should be recorded when interpreting evidence.

For safety-critical systems, decisions should be documented through the relevant risk assessment and management plan.

Choosing the next question

A useful next step is to identify what is known, what is inferred and what needs verification. This avoids treating a general reference as a site diagnosis.

Where a product is considered, confirm the intended use, authorisation and label directions independently of this educational guide.

Use this sequence to frame investigation and control; it is not a dosing protocol.

Expert Insights

About the Reviewer

Frequently Asked Questions

Common questions about this topic, answered by our technical team.

Related Resources

Continue exploring our knowledge base and product information.